Is Regencell Bioscience (NASDAQ:RGC) ready for a correction?

While some millenniums are indifferent towards compulsion space, it makes sense to go over Regencell Bioscience Holdings. We will evaluate if Regencell Bioscience shares are reasonably priced going into February. Is Regencell Bioscience current valuation justified? We will cover the firm valuation to give you a better outlook on taking a position in the stock.
Published over a year ago
View all stories for Regencell Bioscience | View All Stories
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Rifka Kats

This firm has 3.54 M in debt. The company has a current ratio of 0.09, suggesting that it has not enough short term capital to pay financial commitments when the payables are due.
On a scale of 0 to 100, Regencell Bioscience holds a performance score of 6. The company holds a Beta of 1.4893, which implies a somewhat significant risk relative to the market. Let's try to break down what Regencell's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Regencell Bioscience will likely underperform. Although it is vital to follow Regencell Bioscience current trending patterns, it is good to be conservative about what you can do with the information regarding equity existing price patterns. The philosophy towards forecasting future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. We have found twenty-eight technical indicators for Regencell Bioscience, which you can use to evaluate the performance of the company. Please employ Regencell Bioscience jensen alpha, potential upside, accumulation distribution, as well as the relationship between the treynor ratio and expected short fall to make a quick decision on whether Regencell Bioscience historical price patterns will revert.
We determine the current worth of Regencell Bioscience Holdings using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Regencell Bioscience based exclusively on its fundamental and basic technical indicators. By analyzing Regencell Bioscience's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Regencell Bioscience's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Regencell Bioscience. We calculate exposure to Regencell Bioscience's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Regencell Bioscience's related companies.

Regencell Bioscience Investment Alerts

Regencell investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Regencell Bioscience Holdings performance across your portfolios.Please check all investment alerts for Regencell

Regencell Bioscience Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Regencell value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Regencell Bioscience competition to find correlations between indicators driving the intrinsic value of Regencell.

What is driving Regencell Bioscience Investor Appetite?

Regencell Bioscience reported the last year's revenue of 3.11 B. Reported Net Loss for the year was (848.2 K) with profit before taxes, overhead, and interest of 1.97 B.

Margins Breakdown

Regencell profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Regencell Bioscience itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Regencell Bioscience profit margins.
4.23
Profit Margin
9.24
Operating Margin
16.43
EBITDA Margin
Operating Margin9.24
EBITDA Margin16.43
Gross Margin54.86
Profit Margin4.23
Regencell Bioscience Earnings Before Interest Taxes and Depreciation Amortization USD is increasing over the last 6 years. The previous year's value of Regencell Bioscience Earnings Before Interest Taxes and Depreciation Amortization USD was 678,871,711. Further, Regencell Bioscience Earnings Before Interest Taxes and Depreciation Amortization EBITDA is increasing over the last 5 years.

Our take on today Regencell Bioscience rise

Current variance is at 46.15. Regencell Bioscience Holdings is displaying above-average volatility over the selected time horizon. Investors should scrutinize Regencell Bioscience Holdings independently to ensure intended market timing strategies are aligned with expectations about Regencell Bioscience volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Regencell Bioscience's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Regencell Bioscience's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Regencell Bioscience Implied Volatility

Regencell Bioscience's implied volatility exposes the market's sentiment of Regencell Bioscience Holdings stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Regencell Bioscience's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Regencell Bioscience stock will not fluctuate a lot when Regencell Bioscience's options are near their expiration.

Our Conclusion on Regencell Bioscience

Whereas some firms under the drug manufacturers—specialty & generic industry are still a bit expensive, Regencell Bioscience may offer a potential longer-term growth to investors. In closing, as of the 4th of January 2022, our analysis shows that Regencell Bioscience responds to the market. The company is overvalued and projects very small odds of financial turmoil for the next 2 years. Our primary 90 days advice on the company is Cautious Hold.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Regencell Bioscience Holdings. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com